Symposia
The globalization of Chagas disease: an emerging disease in Europe
ISGlobal Symposium
Date: September 7, 2015
Chairs: Joaquim Gascon, Director, IS Global’s Chagas Initiative; Head of the Tropical Medicine and International Health department, Hospital Clínic of Barcelona, Spain
Fabian Gusovsky, Executive Director, CSO Group, Product Creation Headquarters, Eisai Inc., USA
Yves Jackson, Head of Community Care Unit, University Hospitals of Geneva, Switzerland
Chagas disease: the natural history of the disease
Maria Jesus Pinazo, Technical Coordinator Bolivia, CRESIB Barcelona Centre for International Health Research, Spain
Disease systems and their determinants chronic Chagas disease: to treat or not no treat?
Andrea Angheben, Physician, Centre for Tropical Diseases, Negrar, Italy
Chagas disease in Europe: the challenges to face an emerging infection
Isabela Ribeiro, Head of Chagas Disease Clinical Programme, DNDi, Switzerland
Main challenges and potential strategies related with R&D needs
Visceral leishmaniasis – from patient to public health needs: the role of R&D in disease elimination and control
DNDi Symposium
Date: September 7, 2015
Chair: Jose Antonio Ruiz Postigo, Medical Officer, Leishmaniasis Control Programme, Innovative and Intensified Disease Management Unit, Department of Neglected Tropical Diseases, WHO, Switzerland
Shyam Sundar, Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
The treatment of visceral leishmaniasis
Margriet den Boer, Regional Coordinator, KalaCORE (Consortium for the Control and Elimination of Visceral Leishmaniasis); Médecins Sans Frontières (MSF), Amsterdam, NetherlandsTranslating treatment options to control programs
Jorge Alvar, Head of Visceral Leishmaniasis, DNDi, SwitzerlandDeveloping new treatments to address unmet medical needs
Philippe Guérin, Director, Worldwide Antimalarial Resistance Network (WWARN), Churchill Hospital, Oxford, UK
Data pooling opportunities in leishmaniasis: the WWARN experience
The reality of open source drug discovery: a move towards multilateral collaborations
DNDi Symposium
Date: September 7, 2015
Chair: Matthew Todd, Associate Professor, Department of Chemistry, University of Sydney, AustraliaPiero Olliaro, Senior Research Manager, WHO-TDR (Special Programme for Research and Training in Tropical Diseases), Switzerland; Visiting Professor, Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, UK
Re-engineering How we Innovate for Public Health
Charles Mowbray, Head of Drug Discovery, DNDi, Switzerland
The NTD Drug Discovery Booster: an innovative multiparty collaboration on early drug discovery
Paul Willis, Director, Medicines for Malaria Venture, MMV, Switzerland
MMV Malaria Box and Pathogen Projects: The application of Open Science
Samir Brahmachari, Founder & Director of the Council of Scientific and Industrial Research (CSIR), Institute of Genomics & Integrative Biology, India
The Open Source Drug Discovery project
Leonard Sacks, Acting Deputy Director, CDER, Office of Medical Policy, Food and Drug Administration, USA
Creating a global community for clinical drug repurposing and development
Ebola vaccination
Date: September 7, 2015
Chair: Marcel Tanner, Director Emeritus, Swiss TPH, Switzerland
Angela Huttner, Infectious Disease Physician, University Hospitals of Geneva, Switzerland
Phase I testing of the ebola VSV-ZEBOV candidate vaccine: the Geneva files
Olga De Santis, cAd3-EBOZ Lau Investigator, PMU, Lausanne, Switzerland
Safety and immunogenicity of the Chimpanzee-Adenovirus vectored Ebola vaccine: the Lausanne phase I/IIa clinical trial
Amanda Tiffany, Epidemiologist, Epicentre and Médecins Sans Frontères, Switzerland
Malaria prevalence decreased following mass drug administration of malaria chemoprevention during the Ebola outbreak, Monrovia, Liberia, 2014
Graeme Bilbe, Research & Development Director, DNDi, Switzerland
Testing new therapeutics while handling a crisis: ethical and medical considerations
The Japanese contribution to tackling global health challenges
GHIT Symposium
Date: September 8, 2015
Chair: Peter Piot, Dean, London School of Hygiene and Tropical Medicine, UKB.T. Slingsby, CEO, Global Health Innovative Technology Fund, Japan
The Japanese contribution to tackle global health challenges
Graeme Bilbe, Research & Development Director, DNDi, Switzerland
How innovative collaborations can boost R&D for neglected diseases
Kelly Chibale, Founder and Director, UCT Drug Discovery and Development Centre (H3-D), University of Cape Town, and Director, South African Medical Research Council Drug Discovery and Development Research Unit, South Africa
African-led health innovation to tackle global health challenges through partnerships: The H3D
Eric Huber, Project Leader, Swiss TPH, Switzerland
A bitter pill to swallow? How taste-masking and assessment of praziquantel can contribute to the treatment of schistosomiasis in pre-school children.
Neglected tropical diseases: achievements of public-private partnerships
Sanofi Symposium
Date: September 8, 2015
Robert Sebbag, Vice President of Access to Medicines, Sanofi, France
Introduction and context
Jean Jannin, Coordinator, Innovative and Intensified Disease Management Unit, Department of Neglected Tropical Diseases, WHO, Switzerland
Perspectives of management of neglected tropical diseases at the beginning of the century, and improvements as of today
Pierre Buffet, MCUPH, Pierre and Marie Curie University, France
Leishmaniasis management
Bernard Pécoul, Executive Director, DNDi, Switzerland
DNDi, perspectives of partnership
Progress and challenges for the elimination of gambiense sleeping sickness
DNDi & Swiss TPH Symposium
Date: September 8, 2015
Chair: Anne Moore, Guest Researcher, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, USA
Jose-Ramon Franco, Medical Officer, Department of Control of Neglected Tropical Diseases, WHO, Switzerland
Towards the elimination of HAT
Crispin Lumbala, Director, National Sleeping Sickness Control Programme (PNLTHA), Democratic Republic of the Congo
The role of National Control Programmes in HAT elimination and integration into primary healthcare
Philipe Büscher, Head of unit, Parasite Diagnostics, Institute of Tropical Medicine Antwerp, Belgium
The development of new diagnostic tools for sleeping sickness
Antoine Tarral, Head of HAT Clinical Programme, DNDi, Switzerland
A new dawn for sleeping sickness – the development of oral treatments
The development of new treatments for helminth infections
DNDi Symposium
Date: September 8, 2015
Chair: Gautam Biswas, Medical Officer, Preventive Chemotherapy and Transmission Control, Department of Control of Neglected Tropical Diseases, WHO, SwitzerlandGary Weil, Principal Investigator, Death to Onchocerciasis and Lymphatic Filariasis (DOLF); Professor of Medicine and of Molecular Microbiology, Washington University, School of Medicine, USA
Alternative drug regimens and MDA strategies for lymphatic filariasis and onchocerciasis elimination programs
Claudia Pena Rossi, Head of Filariasis Clinical Programme, DNDi, Switzerland
Towards the future: the development of new macrofilaricide treatments
Mark Sullivan, CEO, Medicines Development Ltd., Australia
A novel funding model for drug development in global health: using the Priority Review Voucher for moxidectin
Somphou Sayasone, Research Fellow, National Institute of Public Health, Lao People’s Democratic Republic
Tribendimidine is an efficacious and safe drug against Opisthorchis viverrini: results of a randomized control trial in southern Lao PDR.
Wilma M. Bagchus, Director, EMD Serono, USA
A phase I relative bioavailability study in healthy volunteers after administration of the pediatric formulation of the active enantiomer of praziquantel (L-PZQ)
Where aid meets trade: exploring business approaches and public private partnerships for health
Satellite Symposium
Date: September 8, 2015
Chairs: Koert Ritmeijer (Amsterdam, The Netherlands)
Esther Jurgens (Maastricht, The Netherlands)
Leon Bijlmakers, Radbout University, Nijmegen, The Netherlands
Public-private partnerships for health: considering their features and roles in accelerating universal health coverage
Nathalie Strub-Wourgaft, Medical Director, DNDi, Switzerland
Drugs for Neglected Diseases initiative: public-private partnership in drug development
Judit Barniol, i+solutions, Woerden, The Netherlands
Investing in female condoms. The role of PPPs in the Universal Access to the Female Condom Initiative
Alexander Kohnstamm, PharmAccess, Amsterdam, The Netherlands
Making Health Markets Work for the Poor
Leishmaniasis
Date: September 8, 2015
Chair: Johannes Blum, Professor, Medical Services and Diagnostic, Swiss TPH, Switzerland
Vishal Goyal, Clinical Manager, DNDi, India
Effectiveness, safety profile of new treatments and long-term outcome for kala-azar at public health facilities in Bihar, India
Tapan Bhattacharyya, Research Assistant, London School of Hygiene and Tropical Medicine, UK
IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test
Richard Witzig, Associate Professor, Tulane University School of Medicine, USA
Portable HECT-CL thermotherapy for L. tropica cutaneous leishmaniasis in Aleppo, Syria during 2014
Sakib Burza, Medical Coordinator, Médecins Sans Frontières, India
Post kala-azar dermal leishmaniasis treated with liposomal amphotericin B (AmBisome)
Lourena Costa, graduate student, Faculty of Medicine, Universidade Federal de Minas Gerais, Brazil
Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis
Stefania Varani, Assistant Professor of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy
Innovative approaches to visceral leishmaniasis: 18F-FDG PET/CT as a diagnostic tool and treatment with a single dose of liposomal amphotericin B
African and South-American R&D for Trypanosomiasis
Date: September 9, 2015
Chair: Pascal Maeser, Head of Unit, Swiss TPH, SwitzerlandEnock Matovu, Associate Professor, Malerere University School of Veterinary Medicine, Uganda
A new diagnostic algorithm for Trypanosoma brucei gambiense human African trypanosomiasis (HAT) case detection in a low prevalence setting in North Western Uganda
Quentin Gilleman, Coris BioConcept, BelgiumDevelopment of a rapid diagnostic test for active case detection in sleeping sickness control: recHAT Sero-Strip
Esther Schelling, Group Leader, Deputy Head of Unit, Epidemiology and Public Health Swiss TPH, Switzerland
Migration between Côte d’Ivoire and bordering countries and Human African Trypanosomiasis
Isabela Ribeiro, Head of Chagas Clinical Programme, DNDi, Switzerland
Research and development landscape in Chagas disease
Juan C. Ramirez, Chagas molecular biology group, INGEBI-CONICET, Argentina
High frequency of Trypanosoma cruzi polyclonal infections detected by molecular characterization of natural parasite populations in Chagas disease patients enrolled in clinical trials with antiparasitic drugs
Kathryn M. Jones, Sabin Vaccine Laboratories, Texas Children’s Hospital Houston, USA
Immunogenicity and efficacy of a subunit therapeutic vaccine against Chagas disease
Mycetoma: Addressing the unbearable treatment gap
DNDi & Eisai Symposium
Date: September 10, 2015
Chairs: Mike Everson, Associate Director, Clinical Research, Infectious Diseases, Eisai Product Creation Systems, Eisai Inc., USA
Nathalie Strub-Wourgaft, Medical Director, DNDi, Switzerland
Ed Zijlstra, Director, Rotterdam Centre for Tropical Medicine, The Netherlands; Expert and Consultant, DNDi, Switzerland
Global overview of mycetoma and treatment gaps
Ahmed Fahal, Professor of Surgery, University of Khartoum; Founder, Mycetoma Research Centre, University of Khartoum, Sudan
Clinical aspects, diagnosis, and treatment of mycetoma
Wendy van de Sande, Research Scientist, ErasmusMC, Department of Medical Microbiology & Infectious Diseases, The Netherlands
New concepts in diagnosis for eumycetoma
Nathalie Strub-Wourgaft, Medical Director, DNDi, Switzerland
Potential R&D pathways for new treatment of eumycetoma
Closing Plenary
PL13 Plenary session: Closing Session
Date: September 8, 2015
Roundtable – Challenges in Global health – the way forward
Marcel Tanner, Director Emeritus, Swiss TPH, Basel, Switzerland
Bernard Pécoul, Executive Director, DNDi, Switzerland will participate in the round table discussion
The outlook – a synthesis by the Chairman of the Scientific Committee
Marcel Tanner, Director Emeritus, Swiss TPH, Basel, Switzerland
Presentation by the organizers ECTMIH 2017
Closing words by Congress Co-Chairs
Christoph F.R. Hatz, Head of Department, Medical Services and Diagnostic, Swiss TPH, Basel, Switzerland
Christian Lengeler, Group Leader, Head of Unit, Epidemiology and Public Health, Swiss TPH, Basel, Switzerland Poster Sessions
POSTER SESSION I
Date: September 7, 2015
Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients
E. Diro,* K. Ritmeijer, M. Boelaert, F. Alves, R. Mohammed, C. Abongomera, R. Ravinetto, M. de Crop, H. Fikre, C. Adera, R. Colebunders, H. van Loen, J. Menten, L. Lynen, A. Hailu, J. van Griensven
POSTER SESSION II
Date: September 9, 2015
Nifurtimox Eflornithine Combination Therapy phase IIIb Field trial: Final effectiveness and safety results
O. Valverde Mordt,* S. Bernhard, S. Ghabri, V. Kande, W. Mutombo, M. Ilunga, I. Lumpungu, S. Mutanda, D. Tete, P. Nganzobo, N. Mubwa, S. Blesson, A. Tarral, N. Strub-Wourgaft
Efficacy of oral administration of E1224 in combination with benznidazole on experimental Trypanosoma cruzi infection
I. Ribeiro, L. Diniz, A Mazzeti, L. Mota, M. Bahia
External quality control program for Real-Time PCR testing in a multi-centre, randomised controlled clinical trial in Chagas disease
J. Ramírez, R. Parrado, S. Villarroel, A. de la Barra, M. Rodríguez, L. Irazu, L. Garcia, L. Ortiz, F. Torrico, J. Gascon, I. Ribeiro, A. Schijman
Optimisation of PCR sampling techniques for assessment of parasitological response in patients with Chronic Chagas Disease
L. Flevaud, L. Vargas, M. Nava, F. Torrico, L. Garcia, C. Fux, P. Palma, A. Schijman, B. Blum, J. Fernandes, J. Rode, F. Alves, I. Ribeiro
Population pharmacokinetics of E1224, a prodrug of ravuconazole for the treatment of Chagas disease
I. Ribeiro, F. Torrico, J. Gascon, L. Ortis, B. Blum, F. Alves, M. Everson, F. Duncanson, F. Garcia-Bournissen
Pharmacokinetic drug-drug interaction study of benznidazole and E1224 in healthy male volunteers
I. Ribeiro, E. Feleder, K. Halabe, G. Yerino, A. Otero, B. Blum, J. Fernandes, F. Barreira, F. Duncanson, E. Schuck, M. Everson, F. Garcia-Bournissen, D. Bedor, E. Evene, V. GualanoAn in vitro assay to assess antichagasic candidates for sterile cure
Monica Cal, Jean-Robert Ioset, Matthias Fügi, Pascal Mäser, Marcel Kaiser
POSTER SPEED TALK
SESSION METHODOLOGY
Date: September 9, 2015
Achieving efficiency in clinical data management through Open Clinical integration with a patient monitoring system
M. Ochieng, R. Jitharidkul, S. Okeyo, T. Omollo, R. Owiti, B. Mutinda, M. Waweru, M. Wasunna, R. Omollo*
|
